Holen Sie sich die Stockscreener-App
5.74
0.00%
0.00
Vorhandelsmarkt:
5.70
-0.04
-0.70%
Protara Therapeutics Inc Aktie (TARA) Neueste Nachrichten
Protara Therapeutics completes $75 million stock offering - MSN
Protara Therapeutics Completes $75 Million Stock Offering - TipRanks
Protara Therapeutics Closes $75 Million Public Offering - marketscreener.com
Protara therapeutics raises $75 million in public offering By Investing.com - Investing.com India
Protara Announces Closing of $75 Million Public Offering - The Manila Times
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN
Protara announces proposed public offering - MSN
Is Protara Therapeutics Inc a good long term investmentOptions Trading Strategies & High Return Trading Strategies - earlytimes.in
Protara Therapeutics: Stock Offer Takes the Spotlight - StocksToTrade
Protara Prices $75 Mln Offering To Advance TARA-002 And Broader Pipeline - Nasdaq
Biotech co Protara slides on $75 mln share sale - TradingView
Protara Therapeutics Shares Sink 16% After $75 Mln Public Offering - Nasdaq
Protara Therapeutics (Nasdaq: TARA) prices 13,043,479-share, $75M public deal - Stock Titan
Protara Therapeutics (TARA) Launches $75M Public Offering - GuruFocus
Protara Therapeutics Prices $75 Million Share Offering - marketscreener.com
Will Protara Therapeutics Inc. (1KPA) stock benefit from sector leadershipJuly 2025 Price Swings & Accurate Trade Setup Notifications - Newser
Protara Therapeutics prices $75 million public offering By Investing.com - Investing.com Nigeria
TARA Stock Offering Priced at Lower End of Target Range - GuruFocus
Protara Therapeutics prices $75 million public offering - Investing.com
Protara Announces Pricing of $75 Million Public Offering - The Manila Times
Protara prices public offering of 13.04 million shares at $5.75 each - marketscreener.com
Protara Announces Pricing of $75 Million Public Offering - GlobeNewswire Inc.
Key Managers Announced for TARA Offering - GuruFocus
Protara Therapeutics Launches Offering of Securities - marketscreener.com
Protara Therapeutics stock tumbles after $75M public offering By Investing.com - Investing.com Canada
Protara Therapeutics announces $75 million public offering - Investing.com
Protara Therapeutics stock tumbles after $75M public offering - Investing.com
Protara Therapeutics announces $75 million public offering By Investing.com - Investing.com South Africa
Protara Announces Proposed Public Offering - The Manila Times
Protara Therapeutics Announces $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Protara Therapeutics (Nasdaq: TARA) starts $75M stock and pre-funded warrant sale - Stock Titan
Protara Therapeutics (NASDAQ:TARA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Protara’s cell therapy touts BCG-naïve treatment potential in Phase II - Yahoo Finance
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients - marketscreener.com
Protara Therapeutics: End Of 2025 Proving Eventful Indeed (NASDAQ:TARA) - Seeking Alpha
Why Protara Therapeutics Inc. (1KPA) stock is listed among top recommendationsEarnings Overview Report & Daily Stock Trend Reports - Newser
Protara Therapeutics (NASDAQ:TARA) Receives Buy Rating from HC Wainwright - Defense World
HC Wainwright & Co. Reiterates Protara Therapeutics (TARA) Buy Recommendation - Nasdaq
TARA: HC Wainwright & Co. Reiterates 'Buy' Rating with $23 Targe - GuruFocus
TARA: TARA-002 shows 69% six-month CR and strong safety in BCG naive NMIBC, advancing to registrational trial - TradingView
Protara Reports Updated Interim Phase 2 Data Of TARA-002 In Non-muscle Invasive Bladder Cancer - RTTNews
Protara Therapeutics reports positive results from bladder cancer study - Seeking Alpha
Protara Therapeutics, Inc. (TARA) Jumps 14.6% in Pre-market Trading: After Positive Data Release - Stocks Telegraph
Protara Therapeutics (TARA) Reveals Promising Data from Phase 2 Bladder Cancer Trial - GuruFocus
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial - TradingView
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients - marketscreener.com
Is Protara Therapeutics Inc. (1KPA) stock attractive for dividend growthTrade Entry Summary & Safe Capital Allocation Plans - Newser
Adversity is less terrifying than hope: Protara Therapeutics Inc (TARA) - Setenews
Will Protara Therapeutics Inc. (1KPA) stock sustain uptrend momentum2025 EndofYear Setup & Risk Adjusted Swing Trade Ideas - Newser
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close - Nasdaq
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):